News

CapitalSoft Inc. Strengthens Market Position with Laru Technology

CapitalSoft Inc. Strengthens Market Position with Laru Technology

CapitalSoft Inc. Strengthens Market Position with Laru Technology

In a ground-breaking move, CapitalSoft Inc. has taken significant steps to fortify its position in the financial technology space by acquiring the assets of Laru Technologies. Known for its advanced fraud detection and risk management solutions for electronic banking, Laru Technologies brings a wealth of experience to CapitalSoft's ebpIQ venture.

A Partnership for Enhanced Financial Security

Founded in 2004, Laru Technologies has established itself as a reputable name, specializing in bank security solutions that effectively help financial institutions to monitor, prevent, and resolve fraudulent activities in ACH and wire transfers. The organization's suite of solutions analyzes each transaction to safeguard against account takeovers, malware threats, and unauthorized fund transfers.

The Power of Innovation

As Laru integrates into CapitalSoft, its legacy of innovation and customer service will significantly boost the capabilities of the ebpIQ initiative. This collaboration aims to enhance software solutions that maximize technology investments, as emphasized by Vic Cizmarik, President of CapitalSoft. He expressed a commitment to continually improving the ebpIQ offering and incorporating valuable user feedback.

Viking Mergers & Acquisitions: Key to the Deal

The successful acquisition was facilitated by Viking Mergers & Acquisitions, which played a crucial role throughout the process. The founder of Laru Technologies, reflecting on the diligent work of the Viking team, praised their contribution to closing the deal. Team members Andrew Hakkarainen, Christian Aunspaugh, and Max Roix were instrumental in aligning both parties to reach an agreement for the benefit of all involved.

A Testament to Market Confidence

Christian Aunspaugh noted that this acquisition marks the second transaction for Laru and reinforces the company's standing in the market. By integrating into a strategic buyer like CapitalSoft, which already operates within multiple SaaS and software verticals, Laru is poised for immediate growth and innovation.

The Future Outlook for Laru Technologies

With the transition now complete, Laru Technologies will embark on a new chapter as part of a larger strategic platform focused on enhancing the security of electronic bank transactions. The collaboration between the two companies promises to deliver enhanced value and foster innovation across the financial software landscape.

About Viking Mergers and Acquisitions

Viking Mergers and Acquisitions has been providing M&A services to small and middle-market business owners since 1996. Well-regarded in the southeastern U.S., Viking has facilitated the sale of over 900 businesses, boasting an impressive 85% close rate at an average of 96% of market value. For anyone seeking a free confidential business valuation or additional information, visiting the Viking website is recommended.

Frequently Asked Questions

What is the significance of the CapitalSoft and Laru Technologies acquisition?

This acquisition enhances CapitalSoft's capabilities in fraud detection and risk management within the financial technology sector.

When was Laru Technologies founded?

Laru Technologies was founded in 2004 and has since provided comprehensive bank security solutions.

How will this acquisition benefit customers?

Customers will experience improved offerings through the enhanced ebpIQ initiative, leveraging Laru's security innovations.

Who facilitated the acquisition?

The deal was facilitated by Viking Mergers & Acquisitions, known for its expertise in business transactions.

What is the vision of CapitalSoft following this acquisition?

CapitalSoft aims to deliver innovative solutions while gathering user feedback and investing in product development for long-term success.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading